These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 8637703)

  • 1. Identification of tyrosine residues that are essential for transforming activity of the ret proto-oncogene with MEN2A or MEN2B mutation.
    Iwashita T; Asai N; Murakami H; Matsuyama M; Takahashi M
    Oncogene; 1996 Feb; 12(3):481-7. PubMed ID: 8637703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B.
    Salvatore D; Melillo RM; Monaco C; Visconti R; Fenzi G; Vecchio G; Fusco A; Santoro M
    Cancer Res; 2001 Feb; 61(4):1426-31. PubMed ID: 11245446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A mutation at tyrosine 1062 in MEN2A-Ret and MEN2B-Ret impairs their transforming activity and association with shc adaptor proteins.
    Asai N; Murakami H; Iwashita T; Takahashi M
    J Biol Chem; 1996 Jul; 271(30):17644-9. PubMed ID: 8663426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B.
    Santoro M; Carlomagno F; Romano A; Bottaro DP; Dathan NA; Grieco M; Fusco A; Vecchio G; Matoskova B; Kraus MH
    Science; 1995 Jan; 267(5196):381-3. PubMed ID: 7824936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Full activation of MEN2B mutant RET by an additional MEN2A mutation or by ligand GDNF stimulation.
    Bongarzone I; Vigano E; Alberti L; Borrello MG; Pasini B; Greco A; Mondellini P; Smith DP; Ponder BA; Romeo G; Pierotti MA
    Oncogene; 1998 May; 16(18):2295-301. PubMed ID: 9620546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RET activation by germline MEN2A and MEN2B mutations.
    Borrello MG; Smith DP; Pasini B; Bongarzone I; Greco A; Lorenzo MJ; Arighi E; Miranda C; Eng C; Alberti L
    Oncogene; 1995 Dec; 11(11):2419-27. PubMed ID: 8570194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repair by Src kinase of function-impaired RET with multiple endocrine neoplasia type 2A mutation with substitutions of tyrosines in the COOH-terminal kinase domain for phenylalanine.
    Kato M; Takeda K; Kawamoto Y; Iwashita T; Akhand AA; Senga T; Yamamoto M; Sobue G; Hamaguchi M; Takahashi M; Nakashima I
    Cancer Res; 2002 Apr; 62(8):2414-22. PubMed ID: 11956105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations.
    Asai N; Iwashita T; Matsuyama M; Takahashi M
    Mol Cell Biol; 1995 Mar; 15(3):1613-9. PubMed ID: 7532281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of multiple endocrine neoplasia 2B RET in neuroblastoma cells alters cell adhesion in vitro, enhances metastatic behavior in vivo, and activates Jun kinase.
    Marshall GM; Peaston AE; Hocker JE; Smith SA; Hansford LM; Tobias V; Norris MD; Haber M; Smith DP; Lorenzo MJ; Ponder BA; Hancock JF
    Cancer Res; 1997 Dec; 57(23):5399-405. PubMed ID: 9393766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Only the substitution of methionine 918 with a threonine and not with other residues activates RET transforming potential.
    Cirafici AM; Salvatore G; De Vita G; Carlomagno F; Dathan NA; Visconti R; Melillo RM; Fusco A; Santoro M
    Endocrinology; 1997 Apr; 138(4):1450-5. PubMed ID: 9075701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype.
    Carlomagno F; Salvatore G; Cirafici AM; De Vita G; Melillo RM; de Franciscis V; Billaud M; Fusco A; Santoro M
    Cancer Res; 1997 Feb; 57(3):391-5. PubMed ID: 9012462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of ret oncogenic activation in MEN2 inherited cancer syndromes.
    Xing S; Smanik PA; Oglesbee MJ; Trosko JE; Mazzaferri EL; Jhiang SM
    Endocrinology; 1996 May; 137(5):1512-9. PubMed ID: 8612479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of Ret-Shc-Grb2 complex induced by GDNF, MEN 2A, and MEN 2B mutations.
    Ohiwa M; Murakami H; Iwashita T; Asai N; Iwata Y; Imai T; Funahashi H; Takagi H; Takahashi M
    Biochem Biophys Res Commun; 1997 Aug; 237(3):747-51. PubMed ID: 9299438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RET proto-oncogene mutations are restricted to codons 634 and 918 in mainland Chinese families with MEN2A and MEN2B.
    Zhou Y; Zhao Y; Cui B; Gu L; Zhu S; Li J; Liu J; Yin M; Zhao T; Yin Z; Yu C; Chen C; Wang L; Xiao B; Hong J; Zhang Y; Tang Z; Wang S; Li X; Ning G
    Clin Endocrinol (Oxf); 2007 Oct; 67(4):570-6. PubMed ID: 17573899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease.
    Carlomagno F; Melillo RM; Visconti R; Salvatore G; De Vita G; Lupoli G; Yu Y; Jing S; Vecchio G; Fusco A; Santoro M
    Endocrinology; 1998 Aug; 139(8):3613-9. PubMed ID: 9681515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue-specific carcinogenesis in transgenic mice expressing the RET proto-oncogene with a multiple endocrine neoplasia type 2A mutation.
    Kawai K; Iwashita T; Murakami H; Hiraiwa N; Yoshiki A; Kusakabe M; Ono K; Iida K; Nakayama A; Takahashi M
    Cancer Res; 2000 Sep; 60(18):5254-60. PubMed ID: 11016655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of gene expression induced by RET with MEN2A or MEN2B mutation.
    Watanabe T; Ichihara M; Hashimoto M; Shimono K; Shimoyama Y; Nagasaka T; Murakumo Y; Murakami H; Sugiura H; Iwata H; Ishiguro N; Takahashi M
    Am J Pathol; 2002 Jul; 161(1):249-56. PubMed ID: 12107109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A mutation in the RET proto-oncogene in Hirschsprung's disease affects the tyrosine kinase activity associated with multiple endocrine neoplasia type 2A and 2B.
    Cosma MP; Panariello L; Quadro L; Dathan NA; Fattoruso O; Colantuoni V
    Biochem J; 1996 Mar; 314 ( Pt 2)(Pt 2):397-400. PubMed ID: 8670046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of leukocyte common antigen-related protein on biochemical and biological activities of RET-MEN2A and RET-MEN2B mutant proteins.
    Qiao S; Iwashita T; Furukawa T; Yamamoto M; Sobue G; Takahashi M
    J Biol Chem; 2001 Mar; 276(12):9460-7. PubMed ID: 11121408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mechanisms of development of multiple endocrine neoplasia 2 by RET mutations.
    Takahashi M; Asai N; Iwashita T; Murakami H; Ito S
    J Intern Med; 1998 Jun; 243(6):509-13. PubMed ID: 9681851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.